Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as a… Read more
Connect Biopharma Holdings Ltd (CNTB) - Total Liabilities
Latest total liabilities as of September 2025: $11.99 Million USD
Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) has total liabilities worth $11.99 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Connect Biopharma Holdings Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how Connect Biopharma Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Connect Biopharma Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Connect Biopharma Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mermaid Maritime Public Company Limited
PINK:MMMPF
|
USA | $221.69 Million |
|
Actinium Pharmaceuticals Inc
NYSE MKT:ATNM
|
USA | $42.37 Million |
|
Turk Ilac ve Serum Sanayi AS
IS:TRILC
|
Turkey | TL4.21 Billion |
|
Madison County Financial Inc
PINK:MCBK
|
USA | $-96.82 Million |
|
Harmony Electronics
TWO:8182
|
Taiwan | NT$2.25 Billion |
|
Tamul Multimedia Co. Ltd
KQ:093640
|
Korea | ₩36.88 Billion |
|
Business Online PCL
BK:BOL
|
Thailand | ฿453.29 Million |
|
Sol Strategies Inc. Common Shares
NASDAQ:STKE
|
USA | $54.82 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Connect Biopharma Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Connect Biopharma Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Connect Biopharma Holdings Ltd (2018–2024)
The table below shows the annual total liabilities of Connect Biopharma Holdings Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.12 Million | -63.31% |
| 2023-12-31 | $24.85 Million | +47.86% |
| 2022-12-31 | $16.81 Million | -10.69% |
| 2021-12-31 | $18.82 Million | -94.18% |
| 2020-12-31 | $323.20 Million | +232.07% |
| 2019-12-31 | $97.33 Million | +9.73% |
| 2018-12-31 | $88.70 Million | -- |